Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
| العنوان: | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
|---|---|
| المؤلفون: | Luca Scafuri, Brigitta Mucci, Roberto Bianco, Fernanda Picozzi, Simone Carrano, Carlo Buonerba, Martina Pagliuca, Ferdinando Costabile, Pasquale Dolce, Sabino De Placido, Giuseppe Di Lorenzo, Michela Izzo, Davide Bosso, Luigi Formisano, Simona Iaccarino, Vittorio Riccio, Dario Ribera |
| المساهمون: | Buonerba, C., Iaccarino, S., Dolce, P., Pagliuca, M., Izzo, M., Scafuri, L., Costabile, F., Riccio, V., Ribera, D., Mucci, Brigitta, Carrano, S., Picozzi, F., Bosso, D., Formisano, L., Bianco, R., De Placido, S., Di Lorenzo, G. |
| المصدر: | Cancers, Vol 11, Iss 9, p 1259 (2019) Cancers |
| بيانات النشر: | MDPI AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Epidermal growth factor receptor tyrosine kinase inhibitor, Population, Review, epidermal growth factor receptor tyrosine kinase inhibitors, lcsh:RC254-282, law.invention, 03 medical and health sciences, Exon, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Medicine, sex, Epidermal growth factor receptor, Lung cancer, education, non-small cell lung cancer, education.field_of_study, biology, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, respiratory tract diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, Meta-analysis, biology.protein, Non small cell, business, Tyrosine kinase |
| الوصف: | Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a systematic review and meta-analysis of randomized control trials (RCTs) to explore differences in outcomes associated with EGFR-TKIs among subgroups of EGFR-mutant NSCLC patients. Pooled HRs for progression or death (PFS-HRs) and pooled HRs for death (OS-HRs) were compared among sub-groups defined according to baseline clinical and demographic variables as well as type of EGFR mutation. In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12–1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05–1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18–1.63). Male patients, smokers and patients with EGFR exon 21 L858R mutation may derive less benefit from EGFR-TKIs compared to female patients, non-smokers and patients with EGFR exon 19 deletion. |
| اللغة: | English |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a23c90abb625d3798f8b0fe3b7dcd3Test https://www.mdpi.com/2072-6694/11/9/1259Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....04a23c90abb625d3798f8b0fe3b7dcd3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|